Establishment of Prognostic Nomogram for Male Breast Cancer Patients: A Surveillance, Epidemiology and End Results Database Analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study developed a novel nomogram to predict overall survival (OS) and breast cancer-specific survival (BCSS) in male breast cancer (MBC) patients. The nomogram aids clinicians in identifying high-risk individuals and forecasting outcomes for better patient management.
Area Of Science
- Oncology
- Medical Statistics
- Cancer Prognostics
Background
- Male breast cancer (MBC) is a rare malignancy with limited prognostic data.
- Existing studies lack comprehensive predictive models for MBC patient survival.
Purpose Of The Study
- To develop and validate a unique nomogram for predicting overall survival (OS) and breast cancer-specific survival (BCSS) in male breast cancer patients.
- To provide a tool for clinicians to identify high-risk MBC patients.
Main Methods
- Utilized data from the Surveillance, Epidemiology, and End Results (SEER) database (2010-2020).
- Performed univariate and multivariate analyses to identify significant prognostic factors.
- Constructed and validated nomograms for OS and BCSS using ROC curves, calibration plots, and decision curve analysis (DCA).
Main Results
- Included 2143 male breast cancer patients.
- Identified age, grade, surgery, chemotherapy, metastasis, subtype, marital status, race, and AJCC stages as significant predictors for OS and BCSS.
- Validated nomogram demonstrated good discrimination and calibration, with superior DCA results for survival prediction.
Conclusions
- A validated nomogram was successfully developed for predicting OS and BCSS in male breast cancer patients.
- This tool can assist clinicians in risk stratification and survival forecasting for MBC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...